2 weeks Ago By Defense World Staff
Cerity Partners LLC bought a new position in Janux Therapeutics, Inc. ( NASDAQ:JANX – Free Report ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,478 shares of the company’s stock, valued at approximately $239,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC grew its position in Janux Therapeutics by 496.5% during the third quarter.
Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after buying an additional 144,883 shares during the period. Geode Capital Management LLC raised its stake in Janux Therapeutics by 6.2% in the 3rd quarter.
Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after purchasing an additional 38,490 shares during the last quarter. Virtu Financial LLC raised its holdings in Janux Therapeutics by 48.0% in the 3rd quarter.
Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Franklin Resources Inc. grew its holdings in Janux Therapeutics by 64.
5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares during the period.
Finally, Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth $139,000. Institutional investors and hedge funds own 75.39% of the company’s stock.
Analyst Upgrades and Downgrades A number of analysts recently weighed in on the stock. Scotiabank decreased their price target on shares of Janux Therapeutics from $62.00 to $41.
00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd.
Wedbush reissued an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th.
Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $95.25.
Janux Therapeutics Price Performance JANX stock opened at $32.07 on Friday. The firm has a market cap of $1.
90 billion, a PE ratio of -27.41 and a beta of 3.27.
The firm has a 50 day simple moving average of $30.20 and a 200 day simple moving average of $43.23.
Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.
71. Janux Therapeutics ( NASDAQ:JANX – Get Free Report ) last released its earnings results on Thursday, February 27th. The company reported ($0.
36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13.
Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.
As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.
Insider Transactions at Janux Therapeutics In other news, Director Ra Capital Management, L.P. acquired 341,742 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th.
The shares were purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88.
Following the completion of the acquisition, the director now owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. This represents a 3.
67 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd.
The stock was sold at an average price of $32.15, for a total transaction of $107,188.10.
Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.
90 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 10,002 shares of company stock valued at $348,203 over the last three months.
29.40% of the stock is owned by corporate insiders. Janux Therapeutics Company Profile ( Free Report ) Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Featured Articles Five stocks we like better than Janux Therapeutics What Investors Must Know About Over-the-Counter (OTC) Stocks 2 Strong Utilities Plays With Booming Earnings and Room to Grow What is the S&P/TSX Index? Why Smart Investors Don’t Panic in Election Season How to Start Investing in Real Estate Now Is the Time to Buy ServiceNow—The Rebound Is Real Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
